pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 92

Genome Genomics Medicine Development 92

Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. The mRNA-1273.214 booster contains the original Spikevax vaccine and a candidate targeting Omicron BA.1 1 variant of concern.

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Drug Discovery World

APRIL 10, 2023

India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. Hyderabad is recognised as the vaccine hub of India. India’s domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 2.

Genome 52

Genome Genomics Drugs Life Science 52

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Drug Discovery World

AUGUST 16, 2023

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52

RNA Genome Genomics DNA 52

Drug Discovery World

JULY 19, 2023

Evan Floden , CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note.

Genome 52

Genome Genomics Bioinformatics Genetics 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. It is the year 2030.

Genome 342

Genome Genomics Clinical Trials Clinical Trials 342

pharmaphorum

DECEMBER 5, 2022

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccination 96

Vaccination Vaccine Antibody Allergies 96

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Regulation 52

Regulation Vaccination Vaccine Trials 52

Roots Analysis

MARCH 16, 2023

It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. mRNA Therapeutics and Vaccines Delivery Routes Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Scienmag

NOVEMBER 16, 2020

The genomic surveillance system will help public health authorities detect and respond to local outbreaks faster and monitor for viral mutations associated with escape from vaccines once they are deployed The Department for Health and Social Care Testing Innovation Fund has backed the Wellcome Sanger Institute and the COVID-19 Genomics UK (COG-UK) (..)

Genome 42

Genome Genomics Vaccination Vaccine 42

BioPharma Reporter

APRIL 16, 2024

Cytiva has announced the launch of its Xcellerex magnetic mixer â a single-use mixing system designed to address challenges faced by customers engaged in large-scale mAb, vaccine and genomic medicine manufacturing processes.

Genome 52

Genome Genomics Manufacturing Vaccination 52

pharmaphorum

MAY 24, 2021

People who have received two doses of the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines have good protection against the Indian variant of SARS-CoV-2 , according to new UK data. The AZ/Oxford University vaccine was less protective at 60%, lower than its top-line 76% efficacy against the original ‘wild-type’ SARS-CoV-2 strain.

Vaccination 123

Vaccination Vaccine Genome Genomics 123

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . This process requires the sequence of the viral protein, which can be determined from its genome and is then coupled with an optimised ‘clamp’ sequence. The University of Queensland. .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.

Genome 52

Genome Genomics Production Marketing 52

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. has carried out more than half of all SARS-CoV-2 genome sequences submitted to the global database. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Genome 52

Genome Genomics Vaccination Vaccine 52

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 82

Vaccination Vaccine Antibody Clinical Trials 82

The Pharma Data

DECEMBER 2, 2020

” VANCOUVER, BC, December 02, 2020 /24-7PressRelease/ — Eyam Vaccines and Immunotherapeutics (EYAM) today announced that former President and CEO of Genome Prairie is joining EYAM. Additional information about Dr. Pontarollo advancement of research projects at Genome Prairie can be found here: [link] … -at-u-of-s.

Vaccination 52

Vaccination Vaccine Genome Genomics 52

STAT News

FEBRUARY 22, 2023

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. Moderna will fund preclinical research studies run by the two companies using Life Edit’s tools based on CRISPR technologies that allow scientists to make precise changes to the human genome.

Gene Editing 126

Gene Editing Gene Genetic Disease Research 126

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D., In the first article, Allison August, M.D.,

Development 59

Development Drugs Genome Genomics 59

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Manufacturing 246

Manufacturing Vaccination Vaccine Gene Therapy 246

Drug Discovery World

SEPTEMBER 29, 2022

Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. . Progression of vaccines . Allison August, M.D.,

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

STAT News

NOVEMBER 3, 2022

Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can’t get out of its own way. Read the rest…

Genome 98

Genome Genomics Clinical Trials Clinical Trials 98

BioSpace

NOVEMBER 15, 2021

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

Gene Editing 75

Gene Editing Life Science Genome Genomics 75

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Scienmag

SEPTEMBER 15, 2020

15, 2020 — Initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggest that following Arizona’s first reported case of COVID-19 in late January, the state experienced no cases that went undetected […]. — Sept.

Genome 40

Genome Genomics Allergies Genetics 40

Roots Analysis

OCTOBER 30, 2023

The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).

RNA 40

RNA Vaccination Vaccine Development 40

STAT News

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Bacteria 124

Bacteria Genome Genomics Vaccination 124

The Pharma Data

MAY 22, 2023

WHO launches global network to detect and prevent infectious disease threats WHO and partners are launching a global network to help protect people from infectious disease threats through the power of pathogen genomics. COVID-19 highlighted the critical role pathogen genomics plays in responding to pandemic threats.

Genome 52

Genome Genomics Bioinformatics Bacteria 52

XTalks

AUGUST 27, 2020

With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

STAT News

JANUARY 20, 2023

Support for it gained traction as the Covid-19 pandemic highlighted concerns about global vaccine inequity, genomic data-sharing, and more. The December talks productively focused on these issues and concluded with delegates agreeing to another round of negotiation in February.

Genome 119

Genome Genomics Vaccination Vaccine 119

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

Drug Discovery World

DECEMBER 19, 2023

What you will learn: How advances in technology have accelerated drug development How AI can address key bottlenecks in the drug discovery process Which technological advancements are likely to have the greatest impact The role of new technology in the post-launch phase How technology is enabling quicker and more comprehensive characterisation of vaccine (..)

Vaccination 64

Vaccination Vaccine Genome Genomics 64

pharmaphorum

AUGUST 10, 2020

The data mining tool will be used to try to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 changes over time, along with patient genetic information, results of lung and CT scans, and other clinical data.

Genetics 135

Genetics Genome Genomics Vaccination 135

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

Biobanking 130

Biobanking Genome Genomics Clinical Trials 130